Drug Formulary information is intended for use by healthcare professionals. It is not intended to be medical advice. Some of the information, including information about funding for cancer drugs, does not apply to all patients. Cancer treatment plans are unique to each patient. If you are a patient, please speak with your healthcare team to understand how this information applies to you.
Severe weather warning in your area. Please stay indoors and stay safe. Read more
regimen
DARO
- Cancer Type
- Genitourinary, Prostate
- Intent
-
Palliative
- Regimen Category
-
Evidence-Informed
- Funding Program
-
Exceptional Access Program darolutamide - For the treatment of metastatic castration-sensitive prostate cancer (mCSPC), based on criteria
- Drugs Used
- darolutamide
Regimen Monograph
Feb 2026
Patient Info Sheet
Please see Drugs Used for related Patient Information Sheets. Patient Information Sheets are not yet available for this regimen.
Last Updated: July 21, 2026
